4192-28-3

Usage

Chemical Properties

White crystals

Upstream product

• 85-44-9 phthalic anhydride 
• 56-41-7 L-alanin 
• 338-69-2 D-Alanine 
• 42406-36-0 (S)-benzyl 2-(1,3-dioxoisoindolin-2-yl)propanoate 
• 1242459-33-1 C₁₇H₂₅NO₄Si₂ 
• 56-41-7 L-alanine 
• 143563-37-5 (S)-tert-butyl N^α-phthaloylalaninate 
• 73365-03-4 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanal 
• 136918-14-4 phthalimide 
• 897045-43-1 (S)-phthaloylalanine 
• 180287-36-9 (S)-3-[(S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-propionyl]-1-methyl-2-oxo-imidazolidine-4-carboxylic acid tert-butyl ester 
• 1074-82-4 potassium phtalimide 
• 22509-74-6 N-ethoxycarbonylphthalimide 
• 56-41-7 l-alanine 

Downstream Products

• 4500-36-1 ethyl 2-(1,3-dioxoisoindolin-2-yl)propanoate 
• 3401-39-6 N,N-phthaloyl-L-alanine-(4-nitro-phenyl ester) 
• 501121-39-7 2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-N-(2-fluoro-2-(phenylsulfanyl)ethyl)propionamide 
• 5364-23-8 (S)-2-(1,3-dioxoisoindolin-2-yl)-N-phenylpropanamide 
• 3485-84-5 N-vinylphthalimide 
• 1637438-30-2 (Z)-N'-(4-chlorobenzylidene)-2-(1,3-dioxoisoindolin-2-yl)propanehydrazide 

Relevant academic research and scientific papers

Synthesis, spectroscopic characterization, and antifungal activity of some mixed ligand complexes of Zn(II), Cd(II), and Hg(II)

A series of new mixed ligand complexes of Zn(II), Cd(II), and Hg(II) with citronellal thiosemicarbazone [3,7-dimethyl-6-octene-1-a1 thiosemicarbazone (LH)] and N-phthaloyl amino acids (AH) have been synthesized by the reaction of metal(II) chloride with ligands citronellal thiosemicarbazone (DOTSC) and N-phthaloyl glycine [1,3-dihydro-1,3-dioxo-2H-isoindole-2-acetic acid (A1H)] or N-phthaloyl alanine [1,3-dihydro-1,3-dioxo-(methyl)-2H-isoindole-2-acetic acid (A2H)] in 1:1:1 molar ratio in dry refluxing ethanol. All the complexes have been characterized by elemental analyses, molar conductance measurement, molecular weight measurement, IR, and multinuclear NMR (1H and 13C{1H}) spectral studies. IR, 1H, and 13C{1H} NMR spectral studies suggest the involvement of azomethine-N, thiol-S atoms of the thiosemicarbazone moiety and both carboxylate-O of N-phthaloyl amino acid moiety in coordination with central metal(II) ion, and four coordinated geometries have been assigned to these complexes. The free ligands and metal complexes have been screened for their antifungal activity against two fungal strains, Fusarium moniliformae and Macrophomina phaseolina, using the the radial growth method. The results of antifungal activity show that metal complexes show enhanced higher activity than the free ligands. Supplemental materials are available for this article. Go to the publisher's online edition of Phosphorus, Sulfur, and Silicon and the Related Elements to view the free supplemental file. Copyright Taylor & Francis Group, LLC.

Synthesis, structural, and antibacterial studies of some mixed ligand complexes of Zn(II), Cd(II), and Hg(II) derived from citral thiosemicarbazone and N-phthaloyl amino acids

A series of new mixed ligand complexes of Zn(II), Cd(II), and Hg(II) with cis-3,7-dimethyl-2,6-octadienthiosemicarbazone (CDOTSC; LH) and N-phthaloyl amino acids (AH) have been synthesized by the reaction of metal dichloride with ligands CDOTSC and N-phthaloyl derivative of DL-glycine (A1H), L-alanine (A2H), or L-valine (A3H) in a 1:1:1 molar ratio in dry refluxing ethanol. All the isolated complexes have the general composition [M(L)(A)]. The plausible structure of these newly synthesized complexes has been proposed on the basis of elemental analyses, molar conductances, molecular weight measurement, and various spectral (IR, 1H NMR, and 13C NMR) studies, and four coordinated geometries have been assigned to these complexes. All the complexes and ligands have been screened for their antibacterial activity. Copyright Taylor & Francis Group, LLC.

Dynamic kinetic resolution utilizing 2-oxoimidazolidine-4-carboxylate as a chiral auxiliary: Stereoselective synthesis of α-amino acids by Gabriel reaction

A Highly stereoselective Gabriel reaction via dynamic kinetic resolution utilizing 2-oxoimidazolidine-4-carboxylate as a chiral auxiliary was exploited. The reaction of tert-butyl (4S)-1-methyl-3-(2-bromopropionyl)-2- oxoimidazolidine-4-carboxylate (2a) w

Synthesis of new amides based on N-Phthaloyl-α-Amino Acids

N-phthaloyl derivatives of aliphatic α-amino acids were synthesized using phthalanhydride under standard conditions. The optimization reaction carried out by the thermal method to obtain the amides of these N-phthaloyl amino acids resulted in transimitted rather than amidation. The target amides of N-phthaloyl-α-amino acids were obtained by acylation of the amine with the corresponding acid chloroanhydrides in dichloromethane. These results were compared with the results of a similar acylation in a non-polar solvent (benzene). The dependence of the direction of the reaction on the duration of the acylation and the amount of amine used was established. The conditions for the formation of the corresponding N-phthaloyl-α-amino acid amides and asymmetric phthalic acid diamides were found. It is noteworthy that the formation of diamides is directly proportional to the equivalent amount of amine and the duration of the reaction, which makes it possible to purposefully control the synthesis in one reactor.

AMINO ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES

The present disclosure provides certain amino acid derivatives that inhibit NF-kB activation and are therefore useful for the treatment of inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Synthesis of novel phthalimido oxime pseudoesters and evaluation of their cytotoxicity

A series of novel optically pure oxime pseudoesters derivatives were synthesized by the reaction of substitute keto oximes with various N-substituted α-amino acids chlorides in the presence of triethylamine and dichloromethane at 0 °C, and their structures were characterized by IR and 1D-NMR methods. The synthesized compounds were tested for their ability to inhibit the proliferation of human colon cancer cells and human epithelial cells. Some of them were revealed to have a significant cytotoxic effect.

Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer

A series of novel dipeptidyl boronic acid compounds were designed, synthesized and biologically investigated for the inhibition of the β5 subunit of 20S proteasome and several compounds showed high activities with IC50 values of less than 10 nM. Some of these compounds potently inhibited the multiple myeloma (MM) cancer cell lines with IC50 values of less than 10 nM. It was reported that the inhibition of both β2 and β5 subunits strongly increased the cytotoxicity of proteasome inhibitors in solid tumor cells, so some of the compounds were evaluated for the inhibition of the β2 subunit and the solid tumor triple-negative breast cancer cell line MDA-MB-231. The results showed that three compounds were active for both the β2 subunit and the triple-negative breast cancer cell line MDA-MB-231. The in vivo pharmacokinetic results showed that compound 8t had good biological parameters for both ig and iv administrations. An in vivo pharmacodynamic experiment showed that compound 8t inhibited the β5 subunit in whole blood more greatly than the marketed MLN9708 with the same dose at different time periods. A pathological analysis indicated that the injection of compound 8t in the tumor of a triple-negative breast cancer xenograft mice model led to tumor cell necrosis, nucleus condensation, deep staining, cell fragmentation, dissolution and neutrophil infiltration compared with the control group. The data in hand showed that compound 8t might be an effective candidate for the treatment of both MM and triple-negative breast cancer.

Synthesis and application of peptide borate compounds

The invention belongs to the field of drug synthesis, and specifically relates to a series of novel peptide borate compounds or pharmaceutical salts thereof, and a preparation method and pharmaceutical application thereof. The structure of the peptide borate compounds or the pharmaceutical salts thereof is as shown in a formula I which is described in the specification. The compounds of the invention can be used for preparing proteasome inhibitors, and thus can be further used for treating solid tumors and blood tumors.

1-Aminopyridinium Ylides as Monodentate Directing Groups for sp3 C-H Bond Functionalization

1-Aminopyridinium ylides are efficient directing groups for palladium-catalyzed β-arylation and alkylation of sp3 C-H bonds in carboxylic acid derivatives. The efficiency of these directing groups depends on the substitution at the pyridine moiety. The unsubstituted pyridine-derived ylides allow functionalization of primary C-H bonds, while methylene groups are unreactive in the absence of external ligands. 4-Pyrrolidinopyridine-containing ylides are capable of C-H functionalization in acyclic methylene groups in the absence of external ligands, thus rivaling the efficiency of the aminoquinoline directing group. Preliminary mechanistic studies have been performed. A cyclopalladated intermediate has been isolated and characterized by X-ray crystallography, and its reactivity was studied.

Amino acid chiral ligand containing bidentate coordination group, chiral catalyst, and corresponding preparation methods and applications thereof

The present invention relates to an amino acid chiral ligand containing a bidentate coordination group, a chiral catalyst, and corresponding preparation methods and applications thereof. The chiral ligand is prepared from a cheap and easily available amino acid, and the development of the chiral ligand can improve the diversity of the chiral ligand. The chiral Ir (III) catalyst is simply and efficiently prepared from the chiral ligand only through a one-step reaction. The chiral Ir (III) catalyst is characterized in that a bidentate guiding group is introduced to an amino acid framework to change the original coordination mode of the amino acid and Ir in order to enhance the chiral control ability of the amino acid to the Ir(III) catalyst. The chiral Ir(III) catalyst is designed and synthesized for the first time, and the selectivity reaches up to 99% ee when the catalyst is successfully applied to the high-efficiency asymmetric synthesis of chiral gamma-cyclolactam, so the catalyst has superior stereo control ability.